Combining two treatments to target uterine cancer
Official title: Combined ATR and P13k inhibition in uterine cancer
Funded at Dana-Farber Cancer Inst · NIH-11070306 · Data updated 2026-11-12
This study is looking at how two types of cancer treatments, ATR and PI3K inhibitors, can work together to help improve outcomes for people with uterine cancer, especially those with tumors that are under a lot of stress from cell replication.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | May 1, 2024 |
| Project end | April 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $487,638 |
| NIH project number | 5P01CA269021-02 |
| Project ID | NIH-11070306 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with uterine cancer, especially those with endometrioid or clear cell histology and specific genetic alterations.
✕Less likely to help
Patients with uterine cancer who do not have the relevant genetic mutations or those with other types of cancer may not benefit from this research.
What this research studies
This research investigates the combined effects of ATR and PI3K inhibitors on uterine cancer, particularly focusing on tumors with high levels of replication stress. By utilizing advanced screening techniques, the study aims to identify how these two therapies can work together to improve treatment outcomes. The approach involves both laboratory experiments and potential clinical applications, targeting specific genetic alterations found in uterine cancer cells. Patients may be monitored for their response to this combination therapy, which could lead to more effective treatment options.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment strategies for patients with uterine cancer, particularly those with specific genetic mutations.
How similar studies have gone: Other research has shown promising results with similar approaches, indicating potential for success in this area.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Konstantinopoulos, Panagiotis — Dana-Farber Cancer Inst
- Study coordinator: Konstantinopoulos, Panagiotis
Related research
Other NIH-funded projects on the same topics.
-
Modeling to Prevent and Control Uterine Cancer
A national modeling effort uses computer simulations to inform better prevention, screening, and treatment of uterine cancer for women.
-
Comparative modeling to guide uterine cancer care
This grant uses computer models to help doctors and patients understand how to make better decisions about uterine cancer care.
-
Using DNA damage drugs to help the immune system fight uterine cancer
This project combines drugs that increase tumor DNA damage with immunotherapy to help people with recurrent microsatellite-stable uterine cancer who haven't responded to current treatments.
-
Dual ATR and PI3K-targeted therapy for uterine cancer
This project will try combining two drugs that block ATR and PI3K to better stop uterine cancers, especially tumors with ARID1A changes or other DNA replication stress.
-
WEE1-targeted treatment for uterine serous and p53-mutant uterine cancer
Testing a drug that blocks the WEE1 protein to try to shrink uterine serous cancers and other uterine cancers with p53 mutations.
-
Treating uterine (endometrial) cancer by targeting DNA damage and replication stress
This project develops new treatment approaches that exploit DNA repair weaknesses to help women with advanced or recurrent uterine (endometrial) cancer who need additional options.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.